Skip to content
DataLookout
Menu

NCT07169214

Evaluation of Safety, Efficacy, and Pharmacokinetics of BT-114143 Injection in Patients With Abnormal Uterine Bleeding

StatusCompleted
PhasePhase 1
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 4 versions: 4 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Primary completion pushed from Sep 23, 2025 to Apr 28, 2026 Show 5 more changesShow less
    • Eligibility criteria expanded, about 34 words
    • Trial completed
    • Study completion date changed from estimate of Dec 31, 2025 to Apr 28, 2026
    • Secondary endpoints: details revised at 2 of 8 entries
    • Site details revised
  2. Minor Enrollment target: 36 to 39
    • Primary completion date changed from estimate of Oct 31, 2025 to Sep 23, 2025
    v3
  3. Minor Secondary endpoints: details revised at 2 of 8 entriesv2
  4. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

safety evaluation
Timeframe: from the first administration to 2 weeks after the last administration

Secondary (8)

Change of menstrual bleeding volume from baseline
Percentage change of menstrual bleeding volume from baseline
The difference in the number of menstrual bleeding days between the post-treatment period and the baseline period in subjects.
The proportion of subjects with menstrual blood loss ≤ 80 ml after treatment.
The proportion of subjects with a reduction in menstrual blood loss of ≥50 ml after treatment compared with the baseline
Show 3 moreShow less
The proportion of subjects with a reduction in menstrual blood loss of ≥36 ml after treatment compared with the baseline.
The change in the Menorrhagia Impact Questionnaire (MIQ) score from baseline after treatment in subjects.
The change in the Menstrual Discomfort Questionnaire (MDQ) score from baseline after treatment in subjects.

Arms and interventions

low-dose groupExperimental

Subjects received low-dose BT-114143 Injection treatment

Medium-dose groupExperimental

Subjects received Medium-dose BT-114143 Injection treatment

High-dose GroupExperimental

Subjects received High-dose BT-114143 Injection treatment

control groupPlacebo comparator

The subjects receive normal saline treatment.

Drugs: BT-114143 Injection at low dose, BT-114143 Injection at Medium-dose, BT-114143 Injection at High-dose, control group

Sites

1 site in 1 country

  • Peking Union Medical College HospitalBeijing, Beijing Municipality, China